Abstract
Objective: To assess the effectiveness of oseltamivir in reducing the risks of influenza-related secondary complications in otherwise healthy adolescent and adult patients aged ≥ 13 years.Research design and methods: Retrospective cohort analysis utilizing health insurance claims data in the USA (Thomson MarketScan Research Database) from six influenza seasons (October–March) between 2000 and 2006 to identify adults and adolescents (≥ 13 years) with influenza. Patients who received a prescription for oseltamivir within ±1 day of diagnosis were compared with a propensity-matched control group receiving no antiviral treatment. The first claim evidence of influenza was used to establish the study index date. Differences in outcomes were determined using Cox proportional hazards regression and expressed in terms of hazard ratios (HR) with 95% confidence intervals (CI).Main outcome measures: Diagnosis of pneumonia, any respiratory condition, otitis media and its complications, hospitalizations due to p...

This publication has 25 references indexed in Scilit: